Optimer Pharmaceuticals’ (OPTR) second quarter 2011 loss per share of $0.52 was wider than the year-ago loss, but we are encouraged by the FDA approval and subsequent launch of Dificid, an antibiotic which treats a condition known as CDAD. Dificid scores better than currently available treatment options on many parameters.
Particularly, we believe the inclusion of superior recurrence benefits over Vancocin in the product label will provide valuable benefit and help Dificid sales. Further, the deals with Cubist and Astellas are positive for Optimer as it will benefit from their experience in marketing hospital-based antibiotics.
Thus, we have an Outperform recommendation on Optimer with a target price of $9.00. Optimer also currently carries a Zacks #1 Rank (Strong Buy).
OPTIMER PHARMAC (OPTR): Free Stock Analysis Report
Zacks Investment Research
